Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $70.00 to $60.00. They now have an "outperform" rating on the stock.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates [Yahoo! Finance]
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was upgraded by analysts at StockNews.com to a "sell" rating.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Barclays PLC from $76.00 to $55.00. They now have an "overweight" rating on the stock.
Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]